All articles tagged: Opioid use, unspecified, uncomplicated (F11.90)
![]()
HealthDay
25 June at 03.04 PM
ADHD Meds May Help Control Opioid Use Disorder in PregnancyPsychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental Health.Kevin Y. Xu, M.D., M.P.H., from the Washington University School of Medicine in St. Louis, and colleagues used U.S. multistate administrative data to examine the risks and benef |
![]()
HealthDay
20 June at 03.52 PM
About One-Third of Mental Health Facilities Offer Meds for Opioid AddictionAbout one-third of community outpatient mental health treatment facilities (MHTFs) offer medications for opioid use disorder (MOUD), according to a study published online June 18 in JAMA Network Open.Jonathan Cantor, Ph.D., from RAND in Santa Monica, California, and colleagues quantified the availability of MOUD at community outpatien |
![]()
HealthDay
17 June at 04.09 PM
Few Receive Meds for Opioid Use Disorder After Nonfatal OverdoseIn the 12 months after a nonfatal overdose, few Medicare beneficiaries receive medications for opioid use disorder (MOUD) or fill a naloxone prescription, according to a study published online June 17 in JAMA Internal Medicine.Christopher M. Jones, Pharm.D., Dr.P.H., from the Substance Abuse and Mental Health Services Administration in |
![]()
HealthDay
20 January at 12.01 AM
Study IDs Risks to Offspring Associated With Prenatal Opioid ExposurePrenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues com |
![]()
HealthDay
17 January at 11.52 PM
New Rx for Schedule-II Stimulants for ADHD Increased During PandemicIncident use of common behavioral health medications remained relatively stable during the COVID-19 pandemic, with the exception of those for attention-deficit/hyperactivity disorder (ADHD), according to a study published online Jan. 10 in JAMA Psychiatry.Grace Chai, Pharm.D., M.P.H., from the U.S. Food and Drug Administration i |
![]()
HealthDay
09 January at 05.00 PM
Access to Residential Addiction Treatment Centers for Teens LimitedFor adolescents, access to U.S. residential addiction treatment centers is limited and costly, according to a study published in the January issue of Health Affairs.Caroline A. King, M.P.H., from Oregon Health & Science University in Portland, and colleagues identified 160 residential addiction treatment facilities that treated adol |
![]()
HealthDay
08 January at 04.56 PM
Mindfulness-Oriented Recovery Enhancement Boosts Methadone TreatmentTelehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P |
![]()
HealthDay
08 January at 04.56 PM
Mindfulness-Oriented Recovery Enhancement Boosts Methadone TreatmentTelehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P |
![]()
HealthDay
03 January at 04.25 PM
2016 to 2020 Saw Rise in Against-Medical-Advice Discharges for Opioid AdmissionsBefore-medically-advised (BMA) discharges increased to one in six patients from 2016 to 2020 for admissions with opioid use disorder (OUD) and an injection-related infection, according to a research letter published in the Dec. 4 issue of the Journal of the American Medical Association.Ashish P. Thakrar, M.D., from the University |
![]()
Evalytics
22 December at 02.27 PM
Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.Kentucky is seeking federal approval to study ibogaine, a psychedelic drug from West Africa, as a potential treatment for opioid addiction. Ibogaine has shown promise in reducing withdrawal symptoms and cravings, presenting an alternative approach to traditional addiction treatments. |
![]()
HealthDay
21 December at 11.17 PM
FDA Approves DNA Cheek Swab Test to ID Patients at High Risk for Opioid AddictionThe U.S. Food and Drug Administration has approved a first-of-its-kind test -- the AvertD test -- that uses DNA swabbed from a patient's cheek to determine if they have a combination of genetic variants associated with an elevated risk for opioid addiction.The 15 genetic variants detected by the test are involved in the brain reward pathways t |
![]()
Evalytics
18 December at 05.42 PM
Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.Kentucky is launching a pilot program to study the use of the psychedelic drug ibogaine as a potential treatment for opioid addiction, despite its federal illegality. Derived from a West African shrub, ibogaine shows promise in combating the opioid crisis, and this initiative seeks to assess its effectiveness and safety. |
![]()
HealthDay
15 November at 11.02 PM
Opioid Rx Down, but Overdoses and Deaths Up, AMA Report ShowsOpioid prescribing by physicians and other health professionals has decreased for the 13th consecutive year, down nearly 50 percent since 2012, while overdoses and deaths related to illicitly manufactured fentanyl, xylazine, and other synthetic substances continue to increase, according to the Overdose Epidemic Report 2023, released by |
![]()
Evalytics
31 October at 04.46 PM
Telemedicine for Buprenorphine Initiation: Revolutionizing Opioid Use Disorder TreatmentIn recent years, the healthcare industry has witnessed a transformative shift towards telemedicine. This innovative approach to healthcare delivery has proven to be not only convenient but also highly effective, especially in addressing complex issues like opioid use disorder. In this article, we will explore how telemedicine has revolutionized the initiation of buprenorphine treatment for individ |
![]()
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
![]()
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
![]()
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
![]()
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |